This site is intended for patients prescribed SIMPONI (golimumab). If you are a Healthcare Professional then go to the HCP site or if you are a member of the public, please visit our public site.


Please continue to take your medication as instructed by your doctor or pharmacist. If you are concerned that you may have symptoms of COVID-19 or you are concerned about having been in contact with someone who has symptoms of COVID-19 then self-isolate, consult NHS 111 ( and also contact your GP or referring centre (consultant or clinical nurse specialist) for further advice.

Safety Information

This section contains important safety information and side-effects that you should look out for. You should also read the Patient Information Leaflet and Patient Reminder Card before taking SIMPONI.

Further information, including the Patient Information Leaflet can be found at

You should not take SIMPONI if you:

  • Are allergic to golimumab or another ingredient in SIMPONI
  • Have tuberculosis (TB) or another severe infection
  • Have moderate or severe heart failure
  • Are pregnant or breast-feeding

Before you take SIMPONI, you must tell your doctor if you:

  • Recently had, or are due, a vaccine
  • Are going to have an operation, including dental procedures
  • Are planning to get pregnant
  • Have severe asthma, COPD (a type of lung disease) or are a heavy smoker
  • Have a congestive heart condition
  • Have travelled to areas where fungal, TB or other infections are common
  • Are allergic to sugars (including sorbitol and fructose) or latex
  • Have Hepatitis B, or carry the Hepatitis B virus
  • Have ever been diagnosed with any form of cancer
  • Have or get any symptoms of infection
  • Have or develop any heart problems, such as mild heart failure
  • Have or develop problems that affects your nervous system
  • Develop symptoms of lupus
  • Have a fever that does not go away, bruise or bleed easily

Talk to your doctor

Before you take SIMPONI, your doctor will test you for TB. You should also let your doctor know immediately if you notice any of the following during or after your treatment:

Signs of infection (including TB)

  • A persistent cough
  • Weight loss
  • Shortness of breath
  • Tiredness
  • Fever
  • Night sweats
  • Diarrhoea
  • Dental problems
  • Flu-like symptoms
  • Burning sensation when passing urine
  • Wounds

Signs of allergic reaction

  • Swelling of the face, lips, mouth and throat
  • Swelling of the hand, feet or ankles
  • Difficulty swallowing or breathing
  • Skin rash, including hives

Signs of liver problems

  • Yellowing of the skin or eyes
  • Dark brown urine
  • Right-sided abdominal pain
  • Fever
  • Nausea and vomiting
  • Tiredness

Signs of heart failure

  • Shortness of breath
  • Swelling of the feet

If you experience any side effects (including any not listed above), talk to your healthcare professional. You can report side effects via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store – this helps to provide more information on the safety of this medicine.

If you notice anything unusual, contact your healthcare professional, especially if:

  • The injection site continues to bleed
  • The injection is very painful
  • A rash develops around the injection site
  • You get a fever or develop signs of an allergic reaction


For further information about SIMPONI (golimumab) please contact our Medical Information Department at:

Medical Information Department

Merck Sharp & Dohme (UK) Limited

Registered Office:

120 Moorgate



United Kingdom

Tel: 01992 467272


External link

The link you have selected will take you to a third-party website. We do not review or control the content of any third-party site. We do not endorse and are not responsible for the accuracy, content, practices or standards of any third-party sources.

Please confirm you wish to follow this link.

External link

The link you have selected will take you to a third-party website. MSD control the content of the website in relation to MSD products. MSD have no control of the content, on this website, for other company products.

Please confirm you wish to follow this link.


  1. Kanai T et al. Korean J Intern Med 2014; 29(4): 409-15
  2. Olendzki BC et al. Nutr J 2014; 13(5): 1-7.
  3. Brown AC et al. Expert Rev. Gastroenterol. Hepatol 2011; 5(3): 411-25
  4. Pituch-Zdanowksa A et al. Prz Gastroenterol 2015; 10(3): 135-41.
  5. Oliviero F et al. Swiss Med Wkly 2015; 145: w14190.
  6. Clinton CM et al. Arthritis 2015; 2015: Article ID 708152.
  7. Narula N, Fedorak RN. Can J Gastroenterol 2008; 22 (5): 497-504
  8. Bilski J et al. BioMed Res Int 2014; Volume 2014 (Article ID 429031): 1-14.
  9. Benatti FB, Pedersen BK. Nat Rev Rheumatol 2015; 11: 86-97
  10. Nolte K et al. S Afr Fam Pract 2013; 55: 345-9
  11. Metsios GA et al. Expert Rev Clin Immunol 2015; 1-10
  12. Brophy S et al. Semin Arthritis Rheum 42:361-367

SmartJect Pen

Please select the video you would like to watch.

The videos contain sound

Watch video: 50mg pen Watch video: 100mg pen